Literature DB >> 21189229

Activation of suicidal ideation with adjunctive rufinamide in bipolar disorder.

Kenneth R Kaufman1, Peter J Struck.   

Abstract

Antiepileptic drugs are effective psychotropics, especially for bipolar disorder, which leads to their use off-label in treatment-refractory cases. A recent publication suggests that rufinamide may be beneficial adjunctively for bipolar disorder with comorbid psychopathology. This report addresses two negative cases with significant psychiatric adverse effects: increased depression, agitation, and activation of suicidal ideation. These findings suggest that adjunctive rufinamide may lead to increased suicidal ideation in patients with treatment-refractory bipolar disorder. Secondary to the course of severe bipolar disorder, rufinamide cannot be specifically implicated; however, clinicians should be aware of this potential significant adverse effect and monitor high-risk patients. Further studies are required to address rufinamide treatment efficacy and severity of adverse effects in patients with bipolar disorder.
Copyright © 2010 Elsevier Inc. All rights reserved.

Entities:  

Mesh:

Substances:

Year:  2010        PMID: 21189229     DOI: 10.1016/j.yebeh.2010.11.014

Source DB:  PubMed          Journal:  Epilepsy Behav        ISSN: 1525-5050            Impact factor:   2.937


  3 in total

Review 1.  The Pharmacology and Toxicology of Third-Generation Anticonvulsant Drugs.

Authors:  Paul LaPenna; Laura M Tormoehlen
Journal:  J Med Toxicol       Date:  2017-08-16

2.  Apparent dose-dependent levetiracetam-induced de novo major depression with suicidal behavior.

Authors:  Kenneth R Kaufman; Viwek Bisen; Aphrodite Zimmerman; Anthony Tobia; Ram Mani; Stephen Wong
Journal:  Epilepsy Behav Case Rep       Date:  2013-08-13

3.  Epilepsy With Suicide: A Bibliometrics Study and Visualization Analysis via CiteSpace.

Authors:  Yi Guo; Zheng-Yan-Ran Xu; Meng-Ting Cai; Wen-Xin Gong; Chun-Hong Shen
Journal:  Front Neurol       Date:  2022-01-17       Impact factor: 4.003

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.